US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Genomics Immunology and Healthcare ETF

40.00

+1.303.36%

Pre-market: 40.000.00000.00%04:00 EDT

Volume:63.45K

Turnover:2.54M

Market Cap:272.00M

PE:- -

High:40.58

Open:39.41

Low:39.41

Close:38.70

52wk High:41.49

52wk Low:22.33

Shares:6.80M

Float Shares:6.80M

Volume Ratio:0.43

T/O Rate:0.93%

Dividend:0.28

Dividend Rate:0.70%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Berenberg Boosts Price Target on Moderna to $100 From $45, Keeps Hold Rating

MT Newswires Live

Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Merck & Company (MRK) and Pacific Biosciences (PACB)

Vertex Minerals Confirms Reward Gold Mine Resource After ASX‑Driven Update

The Race for the Next Big Weight-Loss Drug is On-and China Wants In

Revolution Medicines Director Lorence H. Kim Disposes of 17,090 Common Shares Worth USD 3.57 Million

Vertex Pharma EVP Jasper Van Grunsven Files Initial Beneficial Ownership Statement

Revolution Medicines Got a 'Miracle' Cancer Drug Approval. Wall Street Wants More.

Revolution Medicines to Gain From Drug Expansion, New Combination Therapies, Morgan Stanley Says

MT Newswires Live

Incyte Says Follicular Lymphoma Treatment Minjuvi Being Funded in Ontario Via FAST Program

MT Newswires Live

Optimi Health to initiate Phase 2 trial of psilocybin-assisted therapy for MDD

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

Incyte Announces Funding of Minjuvi® (Tafasitamab) for Patients with Relapsed or Refractory Follicular Lymphoma Through Ontario's Fast Program

THOMSON REUTERS

Press Release: Candel Therapeutics Appoints Martine Zimmermann, PharmD, to Its Board of Directors

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

Revolution Medicines, Inc. : Morgan Stanley Initiates Coverage with Overweight Rating; Price Target $255

THOMSON REUTERS

BeOne Medicines FY26 H1 Net Income Climbs to Us$464.36 Million; Revenue Rises 32.3% to Us$3.22 Billion

Twist Bioscience Price Target Announced at $45.00/Share by BWS Financial

Moderna Set for 3 Near-Term INT Data Readouts, UBS Says

MT Newswires Live

Twist Bioscience initiated with a Sell at BWS Financial

IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/IDNA/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IDNA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","market":"US","secType":"STK","nameCN":"iShares Genomics Immunology and Healthcare ETF","latestPrice":40,"timestamp":1789675200000,"preClose":38.7,"halted":0,"volume":63447,"hourTrading":{"tag":"盘前","latestPrice":40,"preClose":40,"latestTime":"04:00 EDT","volume":2,"amount":80,"timestamp":1789718413277,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.033591731266149796,"floatShares":6800000,"shares":6800000,"eps":0,"marketStatus":"Pre-Mkt","change":1.3,"latestTime":"09-18 04:18:41 EDT","open":39.41,"high":40.58,"low":39.41,"amount":2543963,"amplitude":0.030233,"askPrice":54.27,"askSize":100,"bidPrice":32.93,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789738200000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":40,"sharesOutstanding":5100000,"nav":38.722209,"aum":263311021.2,"dividendRate":0.007,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":40,"preClose":40,"latestTime":"04:00 EDT","volume":2,"amount":80,"timestamp":1789718413277,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":40,"preClose":40,"latestTime":"17:15 EDT","volume":203,"amount":8225.49,"timestamp":1789679712782,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.4270998634880497,"impliedVol":0.275,"impliedVolPercentile":0.788},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","floatShares":6800000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.4270998634880497,"shares":6800000,"dividePrice":0.28,"high":40.58,"amplitude":0.030233,"preClose":38.7,"low":39.41,"week52Low":22.33,"pbRate":"--","week52High":41.49,"institutionHeld":0,"latestPrice":40,"eps":0,"divideRate":0.007,"volume":63447,"delay":0,"ttmEps":0,"open":39.41,"prevYearClose":26.19,"prevWeekClose":38.06,"prevMonthClose":39.26,"prevQuarterClose":33.75,"fiveDayClose":37.88,"twentyDayClose":40.75,"sixtyDayClose":31.17},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDNA\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"IDNA","amount":0.125421,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2025-12-16","symbol":"IDNA","amount":0.155456,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-06-16","symbol":"IDNA","amount":0.152909,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2024-12-17","symbol":"IDNA","amount":0.11105,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"IDNA","amount":0.11144,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDNA\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-16","recordDate":"2019-12-17","paymentDate":"2019-12-20","value":0.237063,"currency":"USD"},{"executeDate":"2020-06-15","recordDate":"2020-06-16","paymentDate":"2020-06-19","value":0.083667,"currency":"USD"},{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-18","value":0.036209,"currency":"USD"},{"executeDate":"2021-06-10","recordDate":"2021-06-11","paymentDate":"2021-06-16","value":0.052145,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-17","value":0.256358,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDNA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDNA\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666529289","title":"Berenberg Boosts Price Target on Moderna to $100 From $45, Keeps Hold Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2666529289","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666529289?lang=en_us&edition=fundamental","pubTime":"2026-09-11 19:22","pubTimestamp":1789125772,"startTime":"0","endTime":"0","summary":"Moderna (MRNA) has an average rating of hold and mean price target of $112.72, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","IDNA","MRNA","BK4532","BK4551","BK4585","BK4568","BK4534","BK4588","GNOM","BK4533","BK4501","MRNX","BK4548","MRNY","LGHT","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666422435","title":"Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Merck & Company (MRK) and Pacific Biosciences (PACB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666422435","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666422435?lang=en_us&edition=fundamental","pubTime":"2026-09-11 16:20","pubTimestamp":1789114812,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Moderna (MRNA), Merck & Company (MRK) and Pacific ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-moderna-mrna-merck-company-mrk-and-pacific-biosciences-pacb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-moderna-mrna-merck-company-mrk-and-pacific-biosciences-pacb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IHE","MRNA","LU1699723380.USD","TRUH","LU0211331839.USD","PAWZ","LU0648001328.SGD","LU0859254822.USD","LU0965509283.SGD","RXL","LU2491050071.SGD","IE00B2B36J28.USD","LU0432979614.USD","LU0203345920.USD","LU1941712264.USD","LU0203347892.USD","LU1201861249.SGD","SG9999015358.SGD","BMED","LU1066051498.USD","BK4501","LU1941712348.USD","LU2125909247.SGD","BK4139","LU0289739699.SGD","LU2023250843.SGD","LU1066051225.USD","LU2089984988.USD","LU2357627491.SGD","FTXH","LU1917777945.USD","IE00BN8TJ469.HKD","SG9999014559.SGD","LU1116320901.HKD","LU0070302665.USD","LU2360032135.SGD","BK4121","LU1291159041.SGD","BK4534","LU2468319806.SGD","BK4007","IDNA","LU0965508806.USD","LU2461242641.AUD","LU0868494708.USD","FHLC","SGXZ57979304.SGD","LU1923622614.USD","IE00BLSP4452.SGD","LU1069347547.HKD","IE0002141913.USD","LU1035773651.USD","LU1066053197.SGD","LU1430594728.SGD","IE00BBT3K403.USD","LU1057294990.SGD","SG9999001440.SGD","SG9999002224.SGD","LU2324357040.USD","LU0320765646.SGD","SG9999001176.SGD","LU0965509101.SGD","IE00BSNM7G36.USD","BK4551","IE00B1BXHZ80.USD","LU2361044949.HKD","MRK","BK4568","LU0234572021.USD","PPH","BK4516","LU0861579265.USD","SG9999014567.USD","SG9999013999.USD","BK4550","LU0265550946.USD","LU1116320737.USD","LU0266013472.USD","LU1032466523.USD","LU1989772923.USD","LU0942090050.USD","BK4532","LU0124676726.USD","PACB","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU0238689110.USD","LU0689626769.HKD","SG9999014542.SGD","BK4585","LGHT","SG9999014575.USD","LU0130517989.USD","BK4548","LU1934455863.HKD","LU0823416689.USD","WDNA","LU0320765489.SGD","IE00BJJMRZ35.SGD","JDOC","LU1093756168.USD","LU0058720904.USD","LU2125154935.USD","LU1061106388.HKD","IE00BJT1NW94.SGD","LU1585245621.USD","LU1934455194.USD","SG9999001176.USD","LU2361044865.SGD","HRTS","LU0985320562.USD","LU1162221912.USD","GDOC","SG9999002232.USD","LU2433249047.HKD","LU2023250504.SGD","GNOM","LU1934455277.USD","LU1037948541.HKD","LU1929549753.HKD","LU0868494617.USD","VHT","LU0122379950.USD","LU2112291526.USD","LU1571399168.USD","MRNX","BK4559","LU1989771016.USD","LU1989772840.SGD","LU2361045086.USD","LU0965509010.AUD","LU1023059063.AUD","LU0098860793.USD","LU2125154778.USD","LU0130102774.USD","LU1066051811.HKD","LU0208291251.USD","MRNY","LU0980610538.SGD","LU0265550359.USD","SG9999015341.SGD","IE00BLSP4239.USD","LU0006306889.USD","LU0106261372.USD","LU2491049909.HKD","BK4533","LU2491050154.USD","BK4588","IXJ","LU1983299246.USD","LU2106854487.HKD","LU1974910355.USD","LU1093756325.SGD","LU1037948897.HKD","LU2125909593.SGD","IE0009355771.USD","IE000M9KFDE8.USD","LU0477156953.USD","IYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666546340","title":"Vertex Minerals Confirms Reward Gold Mine Resource After ASX‑Driven Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2666546340","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666546340?lang=en_us&edition=fundamental","pubTime":"2026-09-11 13:57","pubTimestamp":1789106251,"startTime":"0","endTime":"0","summary":"Vertex Minerals Ltd. ( ($AU:VTX) ) just unveiled an update. Vertex Minerals has amended its previously released updated mineral resource estimate f...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vertex-minerals-confirms-reward-gold-mine-resource-after-asxdriven-update?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vertex-minerals-confirms-reward-gold-mine-resource-after-asxdriven-update?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0256863811.USD","LU0320765992.SGD","IE00B4R5TH58.HKD","LU2362541513.USD","IDNA","LU1815336091.USD","SGXZ57979304.SGD","VRTX","GNMX","LU2468319806.SGD","IE00BZ9MQY76.HKD","IE00B19Z3B42.SGD","LU1778281490.HKD","LU0889565916.HKD","BK4532","LU1585245621.USD","SG9999001176.SGD","MTX","IBB","BBH","IE00BFTCPJ56.SGD","LU2417539215.USD","IBBQ","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","LU0058720904.USD","IE0002141913.USD","IE00B2B36J28.USD","LU0417517546.SGD","VERX","PBE","IE00BJT1NW94.SGD","TBXU","LU0109394709.USD","LU1093756325.SGD","SGDJ","LU2456880835.USD","BK4588","BIB","BK4533","LU1035775433.USD","LU1559883803.SGD","LU2237438978.USD","LU2362540622.SGD","LU2462157665.USD","BK4567","LU2236285917.USD","LU2362541273.HKD","BK4109","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666111665","title":"The Race for the Next Big Weight-Loss Drug is On-and China Wants In","url":"https://stock-news.laohu8.com/highlight/detail?id=2666111665","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666111665?lang=en_us&edition=fundamental","pubTime":"2026-09-11 08:00","pubTimestamp":1789084800,"startTime":"0","endTime":"0","summary":"SHANGHAI-Chinese biotech companies, rapidly evolving from manufacturers of low-end generic drugs to serious competitors to American pharma giants, are training their sights on one of the most lucrativ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JDOC","NVIB","XBIX","GDOC","BMED","MEDX","IDNA","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666516010","title":"Revolution Medicines Director Lorence H. Kim Disposes of 17,090 Common Shares Worth USD 3.57 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2666516010","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666516010?lang=en_us&edition=fundamental","pubTime":"2026-09-11 05:53","pubTimestamp":1789077203,"startTime":"0","endTime":"0","summary":"Revolution Medicines director Lorence H. Kim disposes of 17,090 common shares worth USD 3.57 millionDirector Lorence H. Kim disclosed sales of 17,090 Revolution Medicines common shares on Sep. 8, 2026","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL1wDHJX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines Director Lorence H. Kim Disposes of 17,090 Common Shares Worth USD 3.57 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","IE0009355771.USD","LU0320765992.SGD","BK4139","IE00B4R5TH58.HKD","PTH","IE00B2B36J28.USD","IE0009354923.USD","IE00BJT1NW94.SGD","RVMD","LU0889565916.HKD","IDNA","IE0002141913.USD","LU0109394709.USD","BBH","IE00BFTCPJ56.SGD","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666515515","title":"Vertex Pharma EVP Jasper Van Grunsven Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2666515515","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666515515?lang=en_us&edition=fundamental","pubTime":"2026-09-11 04:16","pubTimestamp":1789071415,"startTime":"0","endTime":"0","summary":"Vertex Pharma EVP Jasper van Grunsven files initial beneficial ownership statementVertex Pharmaceuticals EVP Jasper van Grunsven filed an initial Form 3 insider ownership statement dated Sept. 8, 2026","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL2ylbPY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU2362540622.SGD","LU0289739699.SGD","IE0002270589.USD","LU0889565916.HKD","LU0320765992.SGD","IDNA","LU1674673428.USD","LU2236285917.USD","LU0823416689.USD","LU0256863811.USD","VRTX","LU0079474960.USD","LU2237438978.USD","IBBQ","BK4532","LU1430594728.SGD","LU1069344957.HKD","LU2468319806.SGD","BK4533","IE00B2B36J28.USD","LU0061475181.USD","LU1585245621.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","LU2456880835.USD","TBXU","PBE","BIB","IE00B894F039.SGD","LU1093756168.USD","LU2417539215.USD","LU2089984988.USD","IE00B19Z3B42.SGD","IE0002141913.USD","GNMX","LU1035775433.USD","SG9999001176.USD","BK4585","IBB","LU1674673691.USD","SG9999013999.USD","LU0109394709.USD","BBH","LU2324357040.USD","IE00BJJMRZ35.SGD","SGXZ57979304.SGD","IE00B19Z9Z06.USD","LU0058720904.USD","LU0432979614.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666518829","title":"Revolution Medicines Got a 'Miracle' Cancer Drug Approval. Wall Street Wants More.","url":"https://stock-news.laohu8.com/highlight/detail?id=2666518829","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666518829?lang=en_us&edition=fundamental","pubTime":"2026-09-11 02:40","pubTimestamp":1789065600,"startTime":"0","endTime":"0","summary":"Revolution Medicines barely had time to celebrate the landmark approval of its pancreatic cancer pill before Wall Street demanded to know what's next.Late last month, regulators approved daraxonrasib ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","IE0009354923.USD","BBH","IE0009355771.USD","RVMD","LU1571399168.USD","PTH","LU2125154935.USD","LU1430594728.SGD","LU0267386448.USD","LU1585245621.USD","IE00BSNM7G36.USD","LU1032466523.USD","LU0432979614.USD","IHE","LU0321505439.SGD","LU1718418525.SGD","IE0002141913.USD","BK4559","LU0882574055.USD","IE00BJT1NW94.SGD","LU0456855351.SGD","FTXH","LU0109394709.USD","LU2360032135.SGD","BMY","LU0868494617.USD","IE00BFTCPJ56.SGD","LU2133065610.SGD","LU1236620750.USD","LU1868837300.USD","LU0114720955.EUR","LU0985481810.HKD","CANC","BK4534","LU0321505868.SGD","LU1983299246.USD","IE00BFXG1179.USD","BK4588","LU0096364046.USD","IDNA","BK4585","LU1093756168.USD","LU1670711040.USD","LU0237698245.USD","LU1868836591.USD","LU1868836757.USD","LU1670710588.SGD","LU0306806265.USD","LU1236620834.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666359288","title":"Revolution Medicines to Gain From Drug Expansion, New Combination Therapies, Morgan Stanley Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2666359288","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666359288?lang=en_us&edition=fundamental","pubTime":"2026-09-10 23:29","pubTimestamp":1789054182,"startTime":"0","endTime":"0","summary":"Revolution Medicines  could see strong long-term growth from Rasonque sales, expansion into earlier treatment, and new drugs and combination therapies pending upcoming trial results, Morgan Stanley said in a note Thursday.Morgan Stanley models about $12 billion in peak risk-adjusted sales across the company's drug portfolio by 2036, with potential sales of about $18 billion before adjusting for development risks, according to the note.The analysts see Rasonque as the company's main commercial base, while zoldonrasib, elironrasib and earlier-stage drugs could provide additional  sources of growth and reduce reliance on one treatment, while combination treatments could become an important long-term driver by helping the company reach patients earlier in treatment and expand into more cancer types.The next 12 to 18 months will include the US launch of Rasonque, updates in colorectal cancer, progress from early-stage drugs and several late-stage studies, though weaker drug uptake or disapp","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BJJMRZ35.SGD","LU0320765992.SGD","PTH","IE00B4R5TH58.HKD","BK4139","IE0009354923.USD","BBH","IE00BJT1NW94.SGD","RVMD","LU0889565916.HKD","IE0009355771.USD","IE00BFTCPJ56.SGD","IDNA","CANC","IE00B2B36J28.USD","IE0002141913.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666591475","title":"Incyte Says Follicular Lymphoma Treatment Minjuvi Being Funded in Ontario Via FAST Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2666591475","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666591475?lang=en_us&edition=fundamental","pubTime":"2026-09-10 22:29","pubTimestamp":1789050571,"startTime":"0","endTime":"0","summary":"Incyte  said Thursday that Minjuvi, a treatment for relapsed or refractory follicular lymphoma, is being funded in Ontario through the province's Funding Accelerated for Specific Treatments, or FAST program.The program enables eligible patients to gain access to the treatment sooner while formal reimbursement processes continue, the company said.Price: 125.89, Change: -0.13, Percent Change: -0.10","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B5TLWC47.USD","FAST","BK4588","BK4104","IDNA","IE00BFXG0V08.USD","BK4550","BK4139","IE00BYQQ9H92.USD","BK4532","BK4585","INCY","BK4567"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666910405","title":"Optimi Health to initiate Phase 2 trial of psilocybin-assisted therapy for MDD","url":"https://stock-news.laohu8.com/highlight/detail?id=2666910405","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666910405?lang=en_us&edition=fundamental","pubTime":"2026-09-10 22:25","pubTimestamp":1789050337,"startTime":"0","endTime":"0","summary":"Optimi Health (OPTH) announces plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for individuals with maj...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/optimi-health-to-initiate-phase-2-trial-of-psilocybin-assisted-therapy-for-mdd-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/optimi-health-to-initiate-phase-2-trial-of-psilocybin-assisted-therapy-for-mdd-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ABVC","GDOC","NVIB","IDNA","HYLG","MEDX","OPTH","PSIL","BK4007","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666599595","title":"IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2666599595","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666599595?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:30","pubTimestamp":1789047000,"startTime":"0","endTime":"0","summary":"Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimens IMUNON retains ownership of its background intellectual property wit","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/10/3359640/0/en/imunon-enters-cooperative-research-and-development-agreement-with-national-cancer-institute-to-advance-clinical-development-of-imnn-001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","GDOC","NCI","NHLD","IMNN","BK4202","BK4139","IDNA","NVIB","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666058595","title":"Incyte Announces Funding of Minjuvi® (Tafasitamab) for Patients with Relapsed or Refractory Follicular Lymphoma Through Ontario's Fast Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2666058595","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666058595?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:00","pubTimestamp":1789045212,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA1BG7FZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4550","BK4588","INCY","BK4139","IDNA","BK4532","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666381593","title":"Press Release: Candel Therapeutics Appoints Martine Zimmermann, PharmD, to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2666381593","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666381593?lang=en_us&edition=fundamental","pubTime":"2026-09-10 20:05","pubTimestamp":1789041900,"startTime":"0","endTime":"0","summary":"-- Regulatory and quality expertise strengthens Board as Candel advances","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4139","BK4585","TM","BK4604","IDNA","BK4099","BK4109","BK4588","BK4539","BK4555","CADL","BK4121","DNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666598627","title":"CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2666598627","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666598627?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:33","pubTimestamp":1789039980,"startTime":"0","endTime":"0","summary":"Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4’s recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina Com","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/10/3359400/0/en/camp4-therapeutics-receives-authorization-in-the-united-kingdom-for-phase-1-2-human-clinical-trial-of-cmp-002-in-patients-with-syngap1-related-disorder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","BK4168","BK4139","CMP","LENZ","NVIB","GDOC","HYLG","BK4200","UBCP","MEDX","BK4211","BK4561","IDNA","ASO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666640045","title":"Revolution Medicines, Inc. : Morgan Stanley Initiates Coverage with Overweight Rating; Price Target $255","url":"https://stock-news.laohu8.com/highlight/detail?id=2666640045","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666640045?lang=en_us&edition=fundamental","pubTime":"2026-09-10 18:09","pubTimestamp":1789034986,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nFWN4520GO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IDNA","IE0009354923.USD","IE0009355771.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0109394709.USD","IE00B2B36J28.USD","LU0889565916.HKD","BBH","RVMD","PTH","IE00BJJMRZ35.SGD","LU0320765992.SGD","IE0002141913.USD","BK4139","IE00BJT1NW94.SGD","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666566940","title":"BeOne Medicines FY26 H1 Net Income Climbs to Us$464.36 Million; Revenue Rises 32.3% to Us$3.22 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2666566940","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666566940?lang=en_us&edition=fundamental","pubTime":"2026-09-10 16:32","pubTimestamp":1789029138,"startTime":"0","endTime":"0","summary":"BeOne Medicines FY26 H1 net income climbs to US$464.36 million; revenue rises 32.3% to US$3.22 billionBeOne Medicines posted GAAP net income of US$464.36 million, swinging from profit of US$95.59 mill","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL4kr7R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","688235","CANC","LU0109394709.USD","IE0009354923.USD","BK4139","BK0239","IE0002141913.USD","IE0009355771.USD","PTH","IE00BJJMRZ35.SGD","BBH","IE00B2B36J28.USD","RVMD","LU0889565916.HKD","IE00BJT1NW94.SGD","IDNA","LU0320765992.SGD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666581105","title":"Twist Bioscience Price Target Announced at $45.00/Share by BWS Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2666581105","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666581105?lang=en_us&edition=fundamental","pubTime":"2026-09-10 05:45","pubTimestamp":1788990300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TWST/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WDNA","GNOM","ARKG","BK4588","IDNA","BK4585","TWST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666311265","title":"Moderna Set for 3 Near-Term INT Data Readouts, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2666311265","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666311265?lang=en_us&edition=fundamental","pubTime":"2026-09-09 23:58","pubTimestamp":1788969505,"startTime":"0","endTime":"0","summary":"Moderna  is set for three data readouts on its individualized neoantigen therapies, or INT, in the near term, serving as potential stock catalysts for the company, UBS Securities said in a Tuesday note.The next major catalyst is the release of phase 3 data on melanoma at an international conference this fall, investors awaiting efficacy on recurrence-free survival and distant metastasis-free survival, the brokerage said.Likely to follow is the phase 2 data on either renal cell carcinoma or muscle-invasive bladder cancer, potentially in 2027, according to UBS. The next readout is probably a phase 3 update on adjuvant non-small cell lung cancer, the investment firm added.UBS has a neutral rating and $150 price target on Moderna.Price: 137.50, Change: -2.83, Percent Change: -2.02","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4533","BK4534","BK4501","BK4551","GNOM","MRNX","BK4548","BK4139","LGHT","MRNY","IDNA","BK4532","BK4585","WDNA","BK4568","MRNA","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666536557","title":"Twist Bioscience initiated with a Sell at BWS Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2666536557","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666536557?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:30","pubTimestamp":1788960619,"startTime":"0","endTime":"0","summary":"BWS Financial initiated coverage of Twist Bioscience (TWST) with a Sell rating and $45 price target Twist’s stock surge in August, driven by Anthro...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/twist-bioscience-initiated-with-a-sell-at-bws-financial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/twist-bioscience-initiated-with-a-sell-at-bws-financial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARKG","BK4588","WDNA","BK4139","BK4585","TWST","GNOM","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666907533","title":"IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2666907533","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666907533?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:30","pubTimestamp":1788957000,"startTime":"0","endTime":"0","summary":"Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET LAWRENCEVILLE, N.J., Sept.  09, 2026 (GLOBE NEWS","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358657/0/en/imunon-announces-full-agenda-and-speaker-lineup-ahead-of-2026-r-d-day-highlighting-imnn-001-clinical-progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRGS","IDNA","MEDX","BK4097","BK4139","HYLG","GDOC","LU2065732104.USD","IMNN","NVIB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}